Clinical Trial

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-25.
Status change: Not Yet Recruiting → Recruiting 2026-03-12
Trial Details
NCT Number NCT07203729
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
Enrollment 184 participants
Start Date 2026-03-01
Primary Completion 2030-06-15 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-16